Private equity firms want $700M for Paras Pharmaceuticals

Actis Advisors and Sequoia Capital Advisors, who together hold a 70 percent stake in Paras Pharmaceuticals, an Indian medical company, are looking for $700 million for their share of the company, according to reports in India. Morgan Stanley has sought bids from Pfizer Inc, GlaxoSmithkline, Sanofi-Aventis, Daiichi Sankyo and Taisho Pharma.

North AmericaUSBriefs